Page last updated: 2024-09-04

febuxostat and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

febuxostat has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abumiya, M; Fujioka, Y; Ito, F; Kameoka, Y; Kobayashi, T; Miura, M; Takahashi, N; Takahashi, S; Yoshioka, T	1

Other Studies

1 other study(ies) available for febuxostat and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Article	Year
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration. International journal of hematology, 2021, Volume: 113, Issue:1 Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Febuxostat; Gene Expression; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2021

Article

Year

The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.

International journal of hematology, 2021, Volume: 113, Issue:1

Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Febuxostat; Gene Expression; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines

2021